Iodamide Meglumine

CHEMBL1201172 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
823.2 g/mol
LogP
Phase
4

This is an iodinated contrast agent used for X-ray imaging of body cavities and blood vessels. The meglumine salt form improves its tolerability compared to sodium salts and reduces toxicity. Like other iodinated contrast agents, it may cause allergic reactions or kidney stress and requires careful screening of patients.

Masse moléculaire

823,2000 g/mol

TPSA

209,00 Ų

Mécanisme d'action

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)NCc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChI=1S/C12H11I3N2O4.C7H17NO5/c1-4(18)16-3-6-8(13)7(12(20)21)10(15)11(9(6)14)17-5(2)19;1-8-2-4(10)6(12)7(13)5(11)3-9/h3H2,1-2H3,(H,16,18)(H,17,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

Molecular Formula

C19H28I3N3O9

HBD / HBA

9 / 10

Liaisons Rotatives

10

Atomes Lourds

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This is an iodinated contrast agent used for X-ray imaging of body cavities and blood vessels. The meglumine salt form improves its tolerability compared to sodium salts and reduces toxicity. Like other iodinated contrast agents, it may cause allergic reactions or kidney stress and requires careful screening of patients.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Iodamide Meglumine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201172. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 29182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.